EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study

John M Kirkwood iD, Lisa A Kottschade, Robert R McWilliams iD, Nikhil I Khushalani iD, Sekwon Jang, Sigrun Hallmeyer iD, David F McDermott iD, Hussein Tawbi iD, Min Che, Cho-Han Lee, Corey Ritchings, Trong Kim Le und 2 weitere

Immunotherapy · 2024

DOI: 10.2217/imt-2022-0292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy, 2024. Verfasst von John M Kirkwood und 13 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232 USA. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb, Checkmate Pharmaceuticals, Harbour BioMed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The OPTIMIzE registry study evaluated real-world outcomes in patients with advanced melanoma receiving immuno-oncology therapies. Materials and methods: Data were collected for patients treated with anti-programmed death 1 (PD-1) monotherapy (nivolumab or pembrolizumab; n = 147) or nivolumab plus ipilimumab (n = 81) from 2015-2017 and followed for ≥3 years.

Results

Nivolumab plus ipilimumab versus anti-PD-1 monotherapy was associated with a nonsignificantly lower risk of death (adjusted HR: 0.83; 95% CI: 0.54-1.28; p = 0.41), higher disease control rate (72 vs 56%; p = 0.04), and stable quality of life, but more grade 3-4 treatment-related adverse events (54 vs 26%; p < 0.0001).

Conclusion

These results support the use of immuno-oncology therapy in advanced melanoma. Melanoma is a serious form of skin cancer that develops from melanocytes, which are pigment cells that give the skin, hair, and other tissues their color. At advanced stages of spread, melanoma can be life-threatening. However, immunotherapy, a type of therapy that helps the body's immune system to destroy cancer cells, allows some patients with advanced melanoma to live longer. The OPTIMIzE study looked at how well patients with advanced melanoma did when treated with different immunotherapies. These patients were treated in a real-world setting, such as a doctor's office, and were not participating in a clinical trial. Compared with clinical trials, real-world studies like the OPTIMIzE study may include a more varied group of patients because of the less selective study enrollment requirements. In the OPTIMIzE study, patients were treated with either a single immunotherapy (nivolumab or pembrolizumab alone) or a combination of two immunotherapies (nivolumab plus ipilimumab). Both single and combination immunotherapies were effective and tolerable. Patients receiving nivolumab plus ipilimumab had greater tumor shrinkage than patients receiving nivolumab or pembrolizumab alone, but with more side effects from their treatment. Despite the occurrence of side effects with both single and combination immunotherapies, patients reported that their quality of life remained stable while being treated. The OPTIMIzE study shows that immunotherapy is effective and tolerable for patients with advanced melanoma in the real-world setting. This information may help doctors with selecting treatments for their patients with advanced melanoma. Clinical Trial Registration: NCT02780089 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaHumansNivolumabIpilimumabQuality of LifeAntineoplastic Combined Chemotherapy ProtocolsRegistries

Stichwörter der Autor:innen

advanced melanomaadverse eventsimmuno-oncologyoverall survivalquality of lifereal-world

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Melanoma Center, UPMC Hillman Cancer Center, Pittsburgh, PA 15232 USA.
  • Department of Oncology, Mayo Clinic, Rochester, MN 55905 USA.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL 33612 USA.
  • Department of Melanoma Research and Therapeutics, Inova Schar Cancer Institute, Fairfax, VA 22031 USA.
  • Department of Oncology, Advocate Medical Group, Park Ridge, IL 60068 USA.
  • Department of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215 USA.

ORCID-Profile: John M Kirkwood, Robert R McWilliams, Nikhil I Khushalani, Sigrun Hallmeyer, David F McDermott, Hussein Tawbi, Scott Ramsey

Förderung

  • Bristol Myers Squibb
  • Checkmate Pharmaceuticals
  • Harbour BioMed
  • Immvira Pharma
  • Iovance Biotherapeutics
  • Ankyra Therapeutics
  • Scopus BioPharma

Zitieren

APA

Kirkwood, J. M., Kottschade, L. A., McWilliams, R. R., Khushalani, N. I., Jang, S., Hallmeyer, S., McDermott, D. F., Tawbi, H., Che, M., Lee, C. H., Ritchings, C., Le, T. K., Park, B., & Ramsey, S. (2024). Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study. Immunotherapy. https://doi.org/10.2217/imt-2022-0292

Vancouver

Kirkwood JM, Kottschade LA, McWilliams RR, Khushalani NI, Jang S, Hallmeyer S, et al. Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study. Immunotherapy. 2024. doi:10.2217/imt-2022-0292

BibTeX
@article{Kirkwood2024,
  author = {Kirkwood, John M and Kottschade, Lisa A and McWilliams, Robert R and Khushalani, Nikhil I and Jang, Sekwon and Hallmeyer, Sigrun and McDermott, David F and Tawbi, Hussein and Che, Min and Lee, Cho-Han and Ritchings, Corey and Le, Trong Kim and Park, Boas and Ramsey, Scott},
  title = {Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study},
  journal = {Immunotherapy},
  year = {2024},
  doi = {10.2217/imt-2022-0292}
}
Kostenlos starten →